Vistogard® is being distributed by BTG Pharmaceuticals as of July 1, 2023. For more details please click here.


Vistogard®* (uridine triacetate) oral granules is the first and only antidote for 5-FU overdose and early-onset, severe or serious 5-FU toxicity


VISTOGARD® is indicated for the emergency treatment of adult and pediatric patients:

  • Following a fluorouracil or capecitabine overdose regardless of the presence of symptoms, or
  • Who exhibit early-onset, severe or life- threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration.

Limitations of use

  • VISTOGARD® is not recommended for the non-emergent treatment of adverse reactions associated with fluorouracil or capecitabine because it may diminish the efficacy of these drugs.
  • The safety and efficacy of VISTOGARD initiated more than 96 hours following the end of fluorouracil or capecitabine administration have not been established.
*A pyrimidine analog

Don't Wait

Stay alert for early, severe 5-FU or capecitabine toxicity


Don't Wait to Act

These RED FLAGS require immediate attention

Unusually severe side effects 3, 8, 9, 12

  • Mucositis (mouth pain, pain on swallowing)
  • Vomiting not well controlled by antiemetics
  • Diarrhea
  • Leukopenia (WBC ‹3500 or falling rapidly)
  • Neutropenia (ANC ‹1000 cells/µL or falling rapidly)9
  • Thrombocytopenia (‹100,000 platelets/µ or falling rapidly)

CNS and cardiac side
effects 4, 10, 15-18

  • Altered mental status
  • Cerebellar ataxia
  • Changes in cognition or consciousness
  • Acute cardiomyopathy
  • Chest pain
  • Heart failure
  • Heart attack
  • Irregular heart beat

Red flags developing early (especially during the first or second treatment cycle and appearing within 96 hours of 5-FU or capecitabine administration) should be addressed promptly. 1-3

You are now leaving the patient site.

The section you selected contains information intended for U.S. healthcare professionals only.
Please certify that you are a U.S. healthcare professional by clicking the link below.